CHM announces positive Phase 1/2 data at ASCO
Filed with ASX · · 8 pages · English
Chimeric Therapeutics Limited on 6ix
Earlier from Chimeric Therapeutics
- Minaris Delivers 100% Manufacturing and Release Success for Chimeric Therapeutics' CDH17 Autologous CAR‑T Program
- Consolidation/Split - CHM
- Chimeric receives $1.8 M advance on FY26 R&D tax incentive
- Half Year Report and Appendix 4D 31 December 2025
- Portfolio streamlined - return of CHM CLTX to City of Hope
Later from Chimeric Therapeutics
- Appointment of Financial Adviser for Strategic Review
- CHM CDH17 Phase 1 clinical trial update - New DL 3 data
- Chimeric receives $1.62M advance on FY26 R&D tax incentive
- CHM ceases enrolment in Phase 1 trial and Company update
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics